ORGANIC
LETTERS
XXXX
Vol. XX, No. XX
Tetrahydroquinolines and Benzazepines
through Catalytic Diastereoselective
Formal [4 þ 2]-Cycloaddition Reactions
between DonorꢀAcceptor Cyclopropenes
and Imines
000–000
Phong M. Truong, Michael D. Mandler, Peter Y. Zavalij, and Michael P. Doyle*
Department of Chemistry & Biochemistry, University of Maryland, College Park,
Maryland 20742, United States
Received May 10, 2013
ABSTRACT
Regio- and diastereoselective Lewis acid catalyzed cycloaddition reactions between imines and donorꢀacceptor cyclopropenes generated from
silyl-protected enoldiazoacetates provide direct access to stable cyclopropane-fused tetrahydroquinolines and, with cyclopropane ring opening
under mild conditions, to 1H-benzazipine derivatives.
3
hypertension (Scheme 1). The preparation of these struc-
c
Access to heterocyclic nitrogen-containing compounds
is of ongoing interest to synthetic and medicinal chemists
because of their abundance in natural products and their
biological activities. Among these heterocycles, tetrahy-
droquinolines and benzazepines represent two important
classes that form the structural motif of many medicinally
2
relevant compounds. As examples, the cyclopropane-
2
,3
tural scaffolds requires multistep syntheses, and this
requirement invites more efficient methodologies for the
1
4
construction of these functionalized structural units.
(
3) (a) Ellis, D.; Kuhen, K. L.; Anaclerio, B.; Wu, B.; Wolff, K.; Yin,
H.; Bursulaya, B.; Caldwell, J.; Karanewsky, D.; He, Y. Bioorg. Med.
Chem. Lett. 2006, 16, 4246–4251. (b) Kondo, K.; Ogawa, H.; Yamashita,
H.; Miyamoto, H.; Tanaka, M.; Nakaya, K.; Kitano, K.; Yamamura,
Y.; Nakamura, S.; Onogawa, T.; Mori, T.; Tominaga, M. Bioorg. Med.
Chem. 1999, 7, 1743–1754. (c) Hou, F.; Zhang, X.; Zhang, G.; Xie, D.;
Chen, P.; Zhang, W.; Jiang, J.; Liang, M.; Wang, G.; Liu, Z.; Geng, R.
N. Engl. J. Med. 2006, 354, 131–140.
fused hydroquinoline 1 is an HIV-1 non-nucleoside reverse
transcriptase inhibitor with potency on the nanomolar
3
scale. Benzazepine tolvaptan (2) is an approved drug
a
3
for treatment of hyponatremia, and benazepril (3) is an
b
angiotensin-converting enzyme inhibitor used to treat
(
4) (a) Wang, L.; Huang, J.; Peng, S.; Liu, H.; Jiang, X.; Wang, J.
Angew. Chem., Int. Ed. 2012, 51, 1–6. (b) Jadhav, A. M.; Pagar, V. V.;
Liu, R. S. Angew. Chem., Int. Ed. 2012, 51, 11809–11813. (c) He, H.; Liu,
W. B.; Dai, L. X.; You, S. L. Angew. Chem., Int. Ed. 2010, 49, 1496–1499.
(5) (a) Doyle, M. P.; McKervey, M. A.; Ye, T. Modern Catalytic
Methods for Organic Synthesis with Diazo Compounds: From Cyclopro-
panes to Ylides; John Wiley & Sons: New York, 1998. Reviews: (b) Doyle,
M. P.; Duffy, R.; Ratnikov, M. O.; Zhou, L. Chem. Rev. 2010, 110, 704–724.
(c) Merlic, C. A.; Zechman, A. L. Synthesis 2003, 1137–1156. (d) Davies,
H. M. L.; Beckwith, R. E. J. Chem. Rev. 2003, 103, 2861–2904. (e)
Davies, H. M. L.; Antoulinakis, E. G. Org. React. 2001, 57, 1–326. (f)
Hodgson, D. M.; Pierard, F. Y. T. M.; Stupple, P. A. Chem. Soc. Rev.
2001, 30, 50–61.
(
1) (a) Joule, J. A.; Mills, K. Heterocyclic Chemistry, 5th ed.; Wiley-
Blackwell: West Sussex, United Kingdom, 2010. (b) Eicher, T.; Hauptmann,
S.; Speicher, A. The Chemistry of Heterocycles: Structure, Reactions,
Syntheses, and Applications, 2nd ed.; Wiley-VCH: Weinheim, Germany,
2
003.
(2) (a) Katritzky, A. R.; Rachwal, S.; Rachwal, B. Tetrahedron 1996,
2, 15031–15070. (b) Renfroe, B.; Harrington, C.; Proctor, G. R.
Heterocyclic Compounds: Azepines; Wiley & Interscience: New York,
984. (c) Kouznetsov, V.; Palma, A.; Ewert, C. Curr. Org. Chem. 2001, 5,
5
1
5
19–551.
1
0.1021/ol401308d r XXXX American Chemical Society